Major adverse events during the first 30 days after stent placement in different subsets of patients according to the C807T genotype
| . | 807 CC . | 807 CT . | 807 TT . | P . |
|---|---|---|---|---|
| Patients with successful procedure, n | 639 | 822 | 298 | |
| Death | 1 (0.2) | 5 (0.6) | 1 (0.3) | .39 |
| Myocardial infarction | 28 (4.4) | 34 (4.1) | 13 (4.3) | .97 |
| Any major adverse event | 30 (4.7) | 50 (6.1) | 16 (5.4) | .51 |
| Patients without abciximab therapy, n | 568 | 722 | 266 | |
| Death | 1 (0.2) | 3 (0.4) | 1 (0.4) | .74 |
| Myocardial infarction | 25 (4.4) | 27 (3.7) | 11 (4.1) | .83 |
| Any major adverse event | 27 (4.8) | 39 (5.4) | 14 (5.3) | .87 |
| Patients <60 y, n | 220 | 285 | 86 | |
| Death | 0 | 0 | 1 (1.2) | |
| Myocardial infarction | 13 (5.9) | 13 (4.6) | 5 (5.8) | .77 |
| Any major adverse event | 15 (6.8) | 16 (5.6) | 6 (7.0) | .82 |
| Patients <50 y, n | 74 | 59 | 20 | |
| Death | 0 | 0 | 1 (5.0) | |
| Myocardial infarction | 6 (8.1) | 4 (6.8) | 1 (5.0) | .88 |
| Any major adverse event | 6 (8.1) | 4 (6.8) | 1 (5.0) | .88 |
| . | 807 CC . | 807 CT . | 807 TT . | P . |
|---|---|---|---|---|
| Patients with successful procedure, n | 639 | 822 | 298 | |
| Death | 1 (0.2) | 5 (0.6) | 1 (0.3) | .39 |
| Myocardial infarction | 28 (4.4) | 34 (4.1) | 13 (4.3) | .97 |
| Any major adverse event | 30 (4.7) | 50 (6.1) | 16 (5.4) | .51 |
| Patients without abciximab therapy, n | 568 | 722 | 266 | |
| Death | 1 (0.2) | 3 (0.4) | 1 (0.4) | .74 |
| Myocardial infarction | 25 (4.4) | 27 (3.7) | 11 (4.1) | .83 |
| Any major adverse event | 27 (4.8) | 39 (5.4) | 14 (5.3) | .87 |
| Patients <60 y, n | 220 | 285 | 86 | |
| Death | 0 | 0 | 1 (1.2) | |
| Myocardial infarction | 13 (5.9) | 13 (4.6) | 5 (5.8) | .77 |
| Any major adverse event | 15 (6.8) | 16 (5.6) | 6 (7.0) | .82 |
| Patients <50 y, n | 74 | 59 | 20 | |
| Death | 0 | 0 | 1 (5.0) | |
| Myocardial infarction | 6 (8.1) | 4 (6.8) | 1 (5.0) | .88 |
| Any major adverse event | 6 (8.1) | 4 (6.8) | 1 (5.0) | .88 |
Numbers in parentheses are percentages.